RESUMO
We case of acute bilateral central serous chorioretinopathy (CSCR) after receiving the first dose of Covishield vaccine in a young, otherwise healthy male with no associated risk factors.
RESUMO
Background: Coronavirus 2019 was declared as a pandemic by the World Health Organization in March 2020. Bereft of specific treatment for the disease, vaccinations and COVID appropriate behavior have come to be the main approaches to combat the pandemic. A number of vaccines have been approved after clearing clinical trials. Hence, it is essential to evaluate the safety profile of each vaccine for ensuring optimum health of the general population. This study was conducted to evaluate the adverse events following CoviShield vaccination in a tertiary care center. Aims and Objectives: The aim of the study was to describe the pattern of adverse effects, treatment given, and comorbidities seen in healthcare workers (HCW) who reported to the adverse drug reaction (ADR) monitoring center in the department of pharmacology Government T.D. Medical College, Alappuzha, following CoviShield vaccination from January 2021 to October 2021. Materials and Methods: A retrospective and descriptive study was carried out at Department of Pharmacology, GTDMCA involving all HCW who reported side effects following CoviShield vaccination in the ADR monitoring centre (AMC) in the Department of Pharmacology, GTDMCA from January 2021 to Oct 2021. Results: Out of 620 HCWs who reported adverse event following vaccination, majority (45%) were from the age group 21–30 years. About 83% of HCWs who reported adverse effect were women. Majority of the respondents (96%) experienced the adverse effects within 24 h. About 88% of respondents experienced these adverse effects after the initial dose alone. Commonly encountered adverse effects were fever (57%), headache (43%), myalgia (38%) etc. Hypertension (7%) was the most common comorbidity seen. Majority of the beneficiaries (70%) took paracetamol for the treatment of the adverse effect. Conclusion: Majority of the vaccinated HCWs experienced minor and self-limiting adverse event following immunization (AEFI) with Chimpanzee Adenovirus Oxford novel CoronaVirus-19. No serious AEFI were reported to the AMC. Despite the record speed at which the vaccine has been developed, it has shown to have a good safety profile considering the millions of doses that have been administered.
RESUMO
An 80-year-old systemically stable female presented with sudden blurring of vision post the first dose of Covishield™, a non-replicating viral vector vaccine. On examination, she was found to have bilateral serous choroidal effusions. A thorough systemic and ocular workup was performed to rule out other causes of choroidal effusion. The effusions resolved with tapering doses of oral and systemic steroids. To the best of our knowledge, at the time of submission, this is the first case of choroidal effusion being reported after the coronavirus disease 2019 (COVID-19) vaccine.
RESUMO
Background: The World Health Organization had proclaimed the outbreak of the novel coronavirus (COVID-19) as a worldwide pandemic on March 11, 2020. Immunization against the disease was the need of the hour to curtail the spread of COVID-19 pandemic. Two vaccines manufactured in India were approved for emergency use authorization initially. They are ChAdox1CoV-19 vaccine – CoviShield and Covaxin. Aims and objectives: This study aimed at assessing the occurrence of adverse effects following immunization (AEFI) among individuals who received the CoviShield vaccine. The objective of this research was to evaluate the type of AEFI among vaccinated beneficiaries and to determine the factors contributing to the development of AEFI. Materials and Methods: A cross-sectional study was done at a teaching hospital in Kerala. All beneficiaries who were administered CoviShield vaccine during the study period, that is, from January 2021 to June 2022 were incorporated in the study. Data regarding AEFI were collected from all vaccinated individuals by direct or telephonic enquiry. Results: The incidence rate of AEFI is 4.5/1000 doses (111/24925 doses). The reporting of AEFI was high among age group of 20–30 years and commonly seen in males (97.3%). The most common AEFI reported with CoviShield vaccine were fever (63%), myalgia (51%), and headache (40%). AEFI were seen commonly after administration of first dose (94%). Only 7 cases (6.3%) of serious AEFI were reported which included death, autoimmune encephalitis, Bell’s palsy, hypotension, and hypersensitivity reactions. There was no significant association between age and type of AEFI (P > 0.05) and dose of vaccine and type of AEFI (P > 0.05). Conclusion: The immunization with CoviShield vaccine is safe among adults (>18 years) with lesser incidence of serious adverse effects. Higher incidence of AEFI is witnessed after administration of first dose and it was commonly seen in males.
RESUMO
Background: SARS-COV-2, a virus that causes coronavirus disease 2019 (COVID-19) was first identified in Wuhan, China, is a highly pathogenic and has spread globally. Numerous vaccines such as Covaxin, Covishield, Sputnic, and Moderna are available for use in Indian population for prophylaxis and treatment of the same. As vaccine campaign kickoff worldwide and with several doses predicted to be administered in near future, there are more possibilities of vaccine related adverse drug reactions. By and large the benefits of vaccinations clearly outweigh the risks. Aim and Objectives: The aim of the study was to identify the possible adverse events following COVID-19 vaccine immunization (AEFI) in Tumkur district, Karnataka. Materials and Methods: Following Ethics Committee approval and permission from District Health Officer (DHO), Tumkur, Karnataka, telephonic interview of 2650 health-care workers who had received their first dose of Covisheild vaccine and willing to respond was done. A follow-up telephonic interview was done after the second dose as well. Their answers were noted, tabulated, and analyzed. Results: About 98% of HCW who received the first dose received the second dose. Following the first dose, 55.3% showed symptoms whereas only 11% showed symptoms after the second. About 81.4% of individuals who showed symptoms post first dose had no symptoms after the second. The most commonly reported symptoms were pain at site of jab, fever, myalgia, cough, and headache. The majority of the individuals recovered with OTC medications. Conclusion: ChAdOx1 nCoV-19 coronavirus vaccine was first administered in health-care workers. There was no study published on the vaccination related ADR in Tumkur population. The vaccination rates were high among HCW with frequency of adverse events following first dose were higher, which was almost similar to the AEFI from the innovator prescribing information.
RESUMO
Background: The current COVID-19 pandemic is one of the greatest public health challenges. The spread of COVID-19 infection continues unabated despite vaccination. Adherence to COVID-19 appropriate behavior is critical to prevent COVID-19 infection. Aim and Objectives: To find out the pattern of COVID-19 appropriate behavior among vaccinated medical students and to estimate the incidence of COVID-19 infection after vaccination. Materials and Methods: A cross-sectional observational study using a questionnaire was carried out for a period of 3 months. The questionnaire was prepared based on the guidelines of Ministry of Health and Family Welfare, Government of India. The data were collected using a pretested Google Form (online digital questionnaire) by means of a web-based survey. Results: About 96.5% of the participants wear face cover or mask while meeting someone or during visit to public places and 91.6% maintain respiratory hygiene, whereas 11.6% spit in the open, 16.1% travel unnecessarily, and 36.8% do not discourage crowd. There is significant (P < 0.05) increase in COVID-19 infection after vaccination. Conclusion: This study suggests that more emphasis should be given on sensitizing the medical students about the standard COVID appropriate behaviors because strict adherence to COVID-19 appropriate behavior is the key to the long-term management of this pandemic.
RESUMO
Background: COVID-19 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was declared Pandemic by the World Health Organization on January 30, 2020. Vaccination represents the best possibility to resolve this pandemic. The current global challenge is the immunization against the SARS-CoV-2. However, the adverse events following immunization (AEFI) of the corona vaccine remains unclear. Aim and Objectives: This observational study aims to represent an accountable data of the AEFI between Covaxin and Covishield in North Indian population. Materials and Methods: The hospital-based prospective and observational study was employed from January 2021 to December 2021 for detecting and monitoring of AEFI in adults. All population vaccinated either covishield or covaxin with both doses were enrolled in the study as targeted population. Post-vaccination vaccinated population were telephonic follow-up with prior consent. Results: A total of 1015 vaccinated individuals were included in this study for assessment of AEFI. After statistical analysis of AEFI between both vaccination at 24 h P = 0.13, 3–7 days 0.4 and complete AEFI P = 0.06 observed. There is no association that was found significant P < 0.05 with the incidence of AEFI. Conclusion: The short-term outcome has not attribute any serious AEFI. This study demonstrated that both vaccines were well-tolerated and safe in generalized population.
RESUMO
Introduction: COVID-19 infection caused by the SARS COV-2 virus is one of the largest pandemics and has affected every nation worldwide. The introduction of different vaccines against COVID-19 infection has bought new hope in the fight against COVID-19, which would decrease the ongoing crisis. These vaccines were approved for emergency purposes, which had fewer clinical trials involving elderly populations. Hence, this study intends to know the safety profile of the COVID-19 vaccine in the elderly population. Methods: In a cross-sectional study, we have collected data regarding the onset of symptoms within 72hrs following first dose of COVID-19 Vaccination among elderly people through a direct interview and by phone call, using a questionnaire. Results: Among 1373 elderly, 445 (32.41%) had no symptoms, while the remaining 928 (67.54%) had developed symptoms. The commonest symptoms were fever 738 (53.75%), pain at local site 536 (39.01%), and body ache 382 (27.82%). All these symptoms were relieved by taking Paracetamol 650mg tablet provided by the vaccination center. The commonest co-morbidities observed were hypertension, diabetes, and ischemic heart disease. There was no mortality. Conclusion: So far, very few studies have been conducted on the elderly population. Our study has an advantage where it has involved a large number of elderly populations. The majority of the elderly in our study received covishield vaccine. We conclude covishield and covaxin vaccines had minor side effects which were selflimiting and can be considered safe in the elderly population despite having multiple co-morbidities. This study endorses that vaccines are safe in the elderly population irrespective of co-morbidities and increasing age.
RESUMO
Objective: The objective of the study was to assess the levels of neutralizing antibody after COVID vaccination in the elderly and compare it with that of the younger persons. The study also aimed at determining the association between the age, sex, and comorbidities and levels of neutralizing antibodies in the young and the old. Subjects and Methods: This was a single-center, cross-sectional, analytical study, conducted in the General Medicine Unit of ACS Medical College, Chennai, from August 2021 to October 2021. Forty?five elderly persons aged 60 years and above and 103 young adults aged 18 years and above and <60 years who were vaccinated with either COVISHIELD or COVAXIN were randomly selected to participate in this study. A detailed history regarding vaccination status, vaccination type, comorbidities, and breakthrough infection was obtained. Blood samples were collected from the participants to analyze the levels of neutralizing antibodies developed after COVID vaccination. Results: The mean age of the older participants was 66.13 ± 5.3 years and the mean age of the younger participants was 36.48 ± 10.9 years. The median level of neutralizing antibody in the younger participants was 97.4% (interquartile range [IQR]: 96.4%–98.0%) and in the older participants was 97.1% (IQR: 93.1%–97.6%). There was a significant difference in the neutralizing antibody level between the younger and the older participants (P = 0.033). There was no significant difference in the neutralizing antibody levels after two doses of either of the two vaccines among both the groups of participants. There was no significant association between the neutralizing antibody titer and sex and comorbidities in both the groups of participants. Five young and two old participants had breakthrough infections after vaccination. The antibody level was higher in persons with breakthrough infection than in those with no breakthrough infection in both the study groups. Conclusion: There was a significant difference in the neutralizing antibody level between the younger and the older participants after COVID vaccination. No significant difference existed in neutralizing antibody response with respect to the type of vaccine in both the study groups. There was no significant association between sex, comorbid status, and neutralizing antibody levels in both the groups.
RESUMO
COVID‑19 infections despite complete vaccination are called breakthrough infections. Breakthrough infections may decrease the vaccination confidence among people. This study was conducted soon after the Covishield vaccine was approved for use in J and K to find out the incidence of breakthrough infections among the recipients of the Covishield vaccine at SKIMS and to find out the associated factors. List of beneficiaries (between February 14, and May 15, 2021) was obtained from the records. Information was gathered telephonically. Incidence of breakthrough infections 6‑month postvaccination was determined. Among 919 participants, the incidence of breakthrough infections was 2.7% (25 cases). The medical profession was associated with a higher frequency of breakthrough infections. Most infections were mild to moderate (96%). One (4%) person required hospitalization. Thus, COVID‑19 infections can occur despite complete vaccination. Increased exposure places an individual at higher risk of breakthrough infections. Therefore, where exposure is high, COVID‑appropriate behavior should be followed despite being vaccinated.
RESUMO
Purpose: The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, and immunogenicity of Covishield vaccine among Health care workers (HCWs) in a tertiary cardiac care centre. Methods: It's a prospective analytical study, conducted at Sri Jayadeva Institute of cardiovascular science and research centre, Mysore, between January 2021 to May 2021. Pre and Post vaccination SARS CoV2 IgG antibodies were assessed among 122 HCWs. Interval between two doses in this study were 4 and 6 weeks. Adverse events following immunisation b(AEFI) and efficacy were assessed and followed up for two month post vaccination. Results: Post vaccination seropositivity was 69.67% in overall study participants. Seropositivity and P/N ratio median value in uninfected and infected group were 60.43% (n ¼ 55),3.47 (IQR: 2.56–5.22) and 96.77% (n ¼ 30),9.49 (IQR: 7.57–12.30) respectively (P < 0.001). Seropositivity and P/N ratio after 4 and 6 weeks were 48.3% (n ¼ 60), 2.95 (IQR: 1.91–4.24), and 83.8% (n ¼ 31), 4.88, (IQR: 3.39–6.43) respectively (P < 0.001). AEFI after first and second dose was 72.9% and 27.8% (p < 0.05) respectively. The most common symptoms after both doses of vaccination were local pain (73% & 88.2%), followed by fever (38.2% & 26.5%). The average duration of symptoms in both doses was 1.75 days. Of 122 participants only 10 (8.19%) had breakthrough infection after two doses of vaccination with mild severity. Conclusion: Covishield vaccine has showed seropositivity of 69.67%.It has acceptable level of safety profile. Seropositivity and P/N ratio has increased with increase in interval between two doses. Though it has not prevented breakthrough infection it has certainly reduced the severity of infection.
RESUMO
Guillain Barre syndrome (GBS)is a collection of clinical syndromes that manifest as an acute inflammatory poly radiculopathy. It usually presents as an acute, non-febrile, monophonic, post infectious illness manifesting as ascending weakness and areflexia. It is an autoimmune disorder characterized by production of antibodies against the myelin and is often triggered by bacterial and viral infections, vaccines against rabies, flu and COVID-19. Here we present a case of 31 years old male with characteristic signs and symptoms of GBSpossibly triggered by Covishield vaccine.
RESUMO
Background: COVID-19 pandemic is a major public health problem worldwide with limited success in treatment regimes. Vaccination has been an important tool for prevention and control of COVID-19. Health-care professionals (HCPs) as frontline warriors in health-care setups were given priority for getting the vaccination. Data generated from clinical trials in the controlled study participants will be limited. This study was planned to document and analyze data regarding vaccine safety in our hospital. Aims and Objectives: The aims of this study were to identify determine the severity and compare the Adverse Events Following Immunization (AEFI) in HCPs vaccinated for COVID-19. Materials and Methods: After taking ethics committee approval (IEC/ASR APPROVAL/033/2021) and obtaining informed consent from 422 study participants, pre-validated questionnaires were administered for all the participants and data were analyzed for comparing the incidence, severity of AEFI’s. Categorical variables will be calculated in Percentages. Chi-square test was done to correlate the AEFI’s in COVISHIELD versus COVAXIN groups. Results: In this study, about 80.5% were below 40 years of age with female predominance in gender distribution. COVISHIELD was administered in 88.1% and COVAXIN in 11.8%. After COVISHIELD 1st dose, myalgia was the most common mild AEFI reported with 79.8% and in 2nd dose, fever was the most common mild AEFI reported with 51.1%. After COVAXIN, feeling tired was the common AEFI in mild (50%) and moderate grades in both doses. AEFIs’ were significantly greater (P < 0.001) in COVISHIELD 1st dose as compared to COVAXIN 1st dose in injection site reaction, feeling feverish, headache, myalgia, nausea and vomiting, flu-like symptoms, and feeling dizzy. Fever was not significantly different in COVISHIELD 1st dose as compared to COVAXIN 1st dose. There is no significant difference between 2nd dose of COVISHIELD and 2nd dose of COVAXIN for injection site reaction, myalgia, nausea, and vomiting. Serious AEFIs’ were not observed in both vaccine groups. Conclusions: The majority of the AEFI’s in this study are mild-to-moderate in nature and associated after the 1st dose of vaccine. None of the participants had serious AEFI’s with both vaccines in the study. The better safety profile of vaccines allows building public faith in a successful vaccine program for our nation.
RESUMO
Background: A massive global human disaster has been created by a recent contagious respiratory infectious disease caused by a novel coronavirus (SARS-CoV-2). The most effective way of controlling infectious diseases is often vaccination. Public vaccine hesitancy is a big problem for public health authorities. Present study was designed to assess the attitudes and hesitancy toward Covid -19 vaccine among healthcare workers and medical students of RUHS-College of Medical Sciences. Material and methods: It was an observational, questionnaire-based study carried out under the department of Pharmacology, RUHS-college of medical sciences Jaipur. The study tool was consists of a digital questionnaire which was prepared in English language. Result: The present study was carried out among 521 health care workers. In this study 48.9% participants were completely agree 31.9% somewhat agree, 13.6% neutral,3.5% somewhat disagree and 2.1% completely disagree to accept covid-19 vaccine without prior employer recommendation. After employer recommendation covid-19 vaccine acceptance was increased. Now 54% participants were completely agree to accept covid-19 vaccine. Hesitancy to covid-19 vaccine was maximal due to possible side effects (65.5%). Conclusions: Acceptability of vaccination in our participants was increased after awareness to vaccine. So by increasing awareness for acceptance of covid-19 vaccine, we can prevent mass rejection of covid-19 vaccine in general population during vaccination program. Vaccine hesitancy must be addressed for successful implementation of covid-19 vaccination program in future
RESUMO
The whole world waiting for the elimination of COVID?19. This is a short series of three cases that presented with optic neuritis. On further inquiry, all had received the Covishield vaccine within 5–12 days just before the presentation, with no history of COVID?19 positive RT?PCR. The range of age was 27–48 years. All patients improved after pulse steroid therapy and are still under follow?up. After being plagued by COVID?19 for nearly 2 years, the whole world wishes for little more than complete eradication of the disease. Our country commenced the much?awaited vaccination drive from Jan 2021. Ophthalmic manifestations have appeared in many forms post?COVID?19, among which neuro?ophthalmic manifestations are infrequent. To the best of our knowledge, this is the first report of a short case series from our country presenting with optic neuritis after COVID?19 vaccination, without any sign of active infection
RESUMO
Background: As there were no vaccines available for any strains of coronaviruses, it was inevitable to develop safe and effective vaccines for the prevention of infection. There were limited data on the safety of the vaccine in the real-world environment, so the present study is undertaken to assess the safety of the vaccine. Aim and Objectives: The objective of the study is to evaluate the safety profile of ChAdOx1-nCoV-19 Coronavirus Vaccine (Covishield) among health care professionals. Materials and Methods: This is 6 months follow-up observation of vaccinated individuals, 545 health care workers have taken Covishield Vaccine for a duration of 1 month in a tertiary care hospital in two doses with 28 days apart. Demographic data such as age, gender, and comorbidities were noted. They were given a World Health Organization-based Adverse Event Following Immunization form to fill if they have any of the symptoms. Their phone numbers were collected to check for any adverse reactions every week after the first dose till the next dose and every month for another 6 months. Results: Adverse reactions were reported by 147 out of 297 vaccinated individuals after the first dose, 40 members out of 248 individuals after the second dose 24 h after vaccination. Pain at the site of infection and body ache/myalgia was seen in 27% of individuals. Reactions were mild in most of the individuals which resolved in a day without medication. Conclusions: Although the frequency of adverse reactions was observed in more individuals, they were mostly mild and self-limiting. This may show that vaccine has an acceptable safety profile in our observation among health care professionals.
RESUMO
Introduction: Covid-19 pandemic is further spreading its leg in India. Indigenous Covishield vaccination drive was started to protect people from the disease. Objective: This observational cross sectional study was conducted to assess the morbidity and mortality pattern amongst Covishield vaccinated people Vs non-vaccinated patients of covid19. Methodology: This observation study was conducted in a dedicated covid-19 hospital. All RTPCR covid-19 patients were included. The data on vaccination against covid-19 amongst the patients was obtained, and analysed using statistical software. Results: The study population comprised of 155 cases of confirmed covid-19 patients of which 24 (15.48%) were fully vaccinated, however 41 (26.45%) and 90 (58.06%) were partially and non-vaccinated respectively. Fully vaccinated people were protected from development of severe form of disease (X2=9.57, d.f=2, p=0.0083). Mortality was significantly less amongst vaccinated group (X2=4.83, d.f=1, p= 0.028). Conclusion: Patients who are completely vaccinated with Covishield vaccine are protected from development of severe form of diseases and deaths and hence mass vaccination of Indian population to overcome the pandemic is required at the earliest.
RESUMO
Covishield is in wide use in India with about 80% efficacy. Serious side effects are still under study. A 30-year-old female presented to us 7 days post-vaccination with a 5-day history of sudden diminution of vision in both eyes. The clinical findings were suggestive of the Vogt-Koyanagi-Harada (VKH) syndrome. She was treated with high-dose oral steroids. At this juncture, the association was unclear. However, it was justified by an acute flare-up of uveitis on day 2 post the second dose of vaccination despite ongoing steroids. A direct correlation of Harada-like syndrome with the Covishield vaccine is observed here
RESUMO
Coronavirus disease 2019 (COVID?19) is known to cause thromboembolic episodes apart from acute respiratory distress syndrome (ARDS). With large vaccine drives all across the world, there are a few case reports on post?vaccine thrombotic events seen with the AZD1222, ChAdO × 1 vaccine. Here, we present two cases of central retinal vein occlusion presenting immediately after receiving the second dose of the Covishield vaccine. Although the causal relationship cannot be drawn, the ophthalmologist should be aware of this adverse reaction
RESUMO
ABSTRACT Mass vaccination campaigns are essential to control the ongoing novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) pandemic. The Covishield vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, which contains the full-length structural spike protein of SARS-CoV-2. Occasionally, it can lead to cutaneous reactions that contribute to fear of vaccination, hesitancy, and incomplete vaccination schedules. We report a case of facial angioedema following the first dose of Covishield in a 63-year-old woman with no previous history of allergies or hypersensitivity to drugs or vaccines. No rebound of angioedema was recorded after the second homologous and third heterologous doses.